Tvardi Therapeutics (TVRD) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tti-101 | Idiopathic Pulmonary Fibrosis | Phase II | Completed | Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis | Jan 03, 2023 | ― |
| Pembrolizumab, Bevacizumab, Atezolizumab, Tti-101 | Hepatocellular Carcinoma | phase1AndPhase2 | Recruiting | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Jun 27, 2022 | ― |
| Fulvestrant, Palbociclib, Ribociclib, Aromatase Inhibitor (Ai), Tti-101 | Breast Cancer | Phase I | Terminated | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer | May 17, 2022 | ― |
| Tti-101 | Melanoma, Colorectal Cancer, Breast Cancer, Non Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Advanced Cancer, Gastric Adenocarcinoma, Hepatocellular Cancer | Phase I | Completed | Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers | Jun 09, 2017 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tti-101 | Phase II | Idiopathic Pulmonary Fibrosis | Completed | Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis | Jan 03, 2023 | ― |
| Pembrolizumab, Bevacizumab, Atezolizumab, Tti-101 | phase1AndPhase2 | Hepatocellular Carcinoma | Recruiting | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Jun 27, 2022 | ― |
| Fulvestrant, Palbociclib, Ribociclib, Aromatase Inhibitor (Ai), Tti-101 | Phase I | Breast Cancer | Terminated | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer | May 17, 2022 | ― |
| Tti-101 | Phase I | Melanoma, Colorectal Cancer, Breast Cancer, Non Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Advanced Cancer, Gastric Adenocarcinoma, Hepatocellular Cancer | Completed | Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers | Jun 09, 2017 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Tvardi Therapeutics Inc. (CH:TVRD) have in its pipeline
Tvardi Therapeutics CH:TVRD is currently developing the following drugs: Tti-101, Pembrolizumab, Bevacizumab, Atezolizumab, Tti-101, Fulvestrant, Palbociclib, Ribociclib, Aromatase Inhibitor (Ai), Tti-101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.